AMAG Pharmaceuticals Inc. (AMAG) Earns “Outperform” Rating from Leerink Swann
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)‘s stock had its “outperform” rating reissued by research analysts at Leerink Swann in a report issued on Thursday. They presently have a $36.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s price target points to a potential upside of 47.18% from the company’s previous close.
A number of other equities analysts have also issued reports on AMAG. Zacks Investment Research raised AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Jefferies Group cut their target price on AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $36.33.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 5.48% during trading on Thursday, hitting $24.46. 582,990 shares of the stock were exchanged. The stock’s market cap is $835.41 million. The stock’s 50 day moving average price is $24.07 and its 200 day moving average price is $23.92. AMAG Pharmaceuticals has a one year low of $17.92 and a one year high of $42.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/amag-pharmaceuticals-inc-amag-earns-outperform-rating-from-leerink-swann.html
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The company had revenue of $127.40 million for the quarter, compared to analyst estimates of $128.52 million. During the same period in the prior year, the company posted $1.12 EPS. AMAG Pharmaceuticals’s quarterly revenue was up 46.7% on a year-over-year basis. Equities research analysts predict that AMAG Pharmaceuticals will post $5.55 EPS for the current year.
Hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,615 shares during the period. Teacher Retirement System of Texas raised its stake in shares of AMAG Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,864 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 589 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 1,666.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,300 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 5,000 shares during the period. Mason Street Advisors LLC purchased a new stake in shares of AMAG Pharmaceuticals during the second quarter worth approximately $162,000. Finally, Societe Generale purchased a new stake in shares of AMAG Pharmaceuticals during the second quarter worth approximately $232,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.